Serological Testing Market Report (2022 to 2030) – Abbott Laboratories Inc., Grifols, S.A., Sysmex Corporation, Thermo Fisher Scientific Inc and Siemens Healthineers AG

Growth Drivers

HIV is a human immunodeficiency virus, usually attacking immunological cells that fight against antigens and infections. Acquired immunodeficiency syndrome (AIDS) is a late-stage HIV infection wherein the immunity system is severely damaged. The infected individuals are likely to develop diseases and acquire infections at a higher rate. From time to time, diagnosis is needed to monitor viral load in such patients. HIV diagnosis is made by rapid antigen test, western blot method, ELISA testing, and RTPCR. According to the Centers for Diseases Control and Prevention, in 2019, nearly 34,800 new HIV cases were registered in the United States. Approximately 80% of transmission of HIV occurs due to not receiving regular care or persons who do not know they have HIV. It is estimated that in 2019 around 1,189,700 people in the United States had HIV. The high HIV transmission rate and an increasing number of HIV-infected patients fuel the serological testing market. 

Serology tests are used to detect antibodies or antigens. Antigens are foreign substances that are primarily responsible for causing diseases. When the body contacts an antigen, the immune system releases antibodies as a defense mechanism and tries to neutralize the antigen. In serological testing, such antibodies and antigens are validated for diagnosing a specific disease and condition, which further helps doctors give proper medical treatment. Serology testing is done by various methods such as hemagglutinin-inhibition tests, enzyme-linked immunosorbent assays (ELISAs), flocculation tests, neutralization tests, and chemiluminescence immunoassays.

The global serological testing market has been analyzed from five different perspectives – product, technology, application, end-user, and region.

Excerpts from ‘Product’

The global serological testing market has been segmented into:

• instruments (Immunoassay Analyzers, ELISA analyzers, ELFA analyzers, and POC analyzers)
• reagents & consumables (ELISPOT Reagents & kits, ELISA Reagents & Kits, Western Blot Reagents & Kits, Rapid Test Reagents & Kits)

Reagents and consumables are leading the global serological testing market owing to the affordability of testing and high consumption of reagents by research institutes and diagnostic laboratories.  

Excerpts From ‘By Technology’

The global serological testing market based on technology has been segmented into:

• Enzyme-Linked Immunosorbent Assay (ELISA)
• Western Blot
• Nucleic Acid Test (NAT)
• Chemiluminescence Microparticle Immunoassay (CMIA)
• Lateral Flow Test

ELISA is leading the global serological testing market owing to less turnaround time for testing, cheap & affordable reagents, long self-life of regents, a high number of infectious diseases screenings, high specificity, high sensitivity, and ELISA analyzers are inexpensive. Additionally, technological advancement, high precision screening, less complex steps required for performing, and many key players are contributing to the growth of ELISA testing segment.

Excerpts from ‘By Region Segmentation’

The global serological testing market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World

North America dominated the global serological testing market. The large share of North America in the global serological testing market is attributed to the recent outbreak of COVID-19, high awareness about communicable diseases, and the prevalence of infectious diseases. Additionally, high healthcare expenditure, developed infrastructure, favorable government policies, swift adoption of new technologies, and rapid approvals of novel serological testing contribute to the growth of the North American serological testing segment.

Table of Content

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.